First-in-human study of KHK2455, a long-acting, potent and selective indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor, in combination with mogamulizumab (Moga), an anti-CCR4 monoclonal antibody, in patients (pts) with advanced solid tumors.

Timothy A. Yap,Solmaz Sahebjam,David S. Hong,Vi Kien Chiu,Emrullah Yilmaz,Sergey Efuni,Dmitri O. Grebennik,Agron Collaku,Eniola Ogunmefun,Yi. Liu,Tomonori Tayama,Robert Raymond Latek,Olivier Rixe

First-in-human study of KHK2455, a long-acting, potent and selective indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor, in combination with mogamulizumab (Moga), an anti-CCR4 monoclonal antibody, in patients (pts) with advanced solid tumors.

2018

Timothy A. Yap
Solmaz Sahebjam
David S. Hong
Vi Kien Chiu
Emrullah Yilmaz
Sergey Efuni
Dmitri O. Grebennik
Agron Collaku
Eniola Ogunmefun
Yi. Liu
Tomonori Tayama
Robert Raymond Latek
Olivier Rixe

3040Background: IDO-1 inhibitors have shown antitumor activity in combination with immunotherapeutic agents in multiple cancers. KHK2455 is a novel and selective oral IDO-1 inhibitor. Unlike other ...

Keywords:

Mogamulizumab
CCR4
Monoclonal antibody
Human study
Pathology
Indoleamine 2,3-dioxygenase
Medicine
Cancer research
antitumor activity
first in human
in patient
long acting

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations